Looks at quality of life in chronic lymphocytic leukemia patients taking acalabrutinib
Reviews past records on quality of life in people with chronic lymphocytic leukemia taking acalabrutinib.
Plain-language title generated from the registry record
Registry title: AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
Key facts
- Where
- Saint-Affrique, FranceSee the site
Where in France
- Saint-AffriqueSaint-Affrique, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06548152
- Record updated
- 27 October 2026
- Original description
QoL is often not assessed in real-world studies; hence, there is limited understanding about the real-world QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on comparing treated and untreated populations. In particular, QoL of patients treated with acalabrutinib has not been evaluated in a real-life setting.Read full original descriptionShow less
AQUALIS: Quality of Life of Patients With Chronic Lymphocytic Leukemia Treated With Acalabrutinib in France: a Retrospective Observational Study Based on Data Extracted From the PLATON Database
QoL is often not assessed in real-world studies; hence, there is limited understanding about the real-world QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on comparing treated and untreated populations. In particular, QoL of patients treated with acalabrutinib has not been evaluated in a real-life setting.
The aim of this study is to describe the QoL of CLL patients treated with acalabrutinib between the treatment initiation and twelve months after, in a real-life setting.
Inclusion: The following patients will be eligible for inclusion in the AQUALIS study :; -Patient enrolled in the PLATON database; -Patient ≥18 years old; -Treatment naïve CLL patient treated with acalabrutinib in a real life setting. Treatment pattern is Acala mono or Acala + Obinutuzumab; -Patient who do not object to his health data collected in PLATON study being re-use for analysis/research purpose; -Patients who started Acala but discontinued before 12 months are also included; Exclusion criteria:; -Pregnant women; -Patients under protection of justice; -Patients over the age of 18 and unable to express their non-opposition; -Patients with prior CLL treatments.